BioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic Cancer
Portfolio Pulse from Vandana Singh
BioLineRx Ltd (NASDAQ:BLRX) announced encouraging data from the pilot phase of the CheMo4METPANC Phase 2 trial for first-line pancreatic cancer. The trial showed a disease control rate of 82%, compared to historic rates of 48%. Based on these results, the trial was amended to become a randomized study with increased enrollment. Earlier this month, the FDA approved BioLineRx's Aphexda for use in patients with multiple myeloma. However, BLRX shares are down 6.28% at $1.94.
September 28, 2023 | 4:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Despite positive trial results and FDA approval for a new drug, BioLineRx's stock is down 6.28%.
The positive trial results and recent FDA approval would typically be expected to boost a company's stock. However, in this case, BioLineRx's stock has fallen, suggesting that other factors may be influencing investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100